TABLE 1.

Review of clinical, cytogenetic, and molecular features: Treatment and outcome of well‐controlled HIV‐positive patients with MDS

HIV						MDS
Case	Age/Sex	Time from HIV (years)	ART	CD4⁺ count (cells/mm³)	Viral load	MDS Subtypes	IPSS	Karyotype	Gene mutations	Progression to AML	MDS treatment	Reference ^a
1	63/ M	13	DDC, AZT, 3TC, ABC, EFV, TDF, TFC	296	< 40	RAEB2/AML	>Int 2	Complex with monosomy 7	NA	Yes	Palliative	Rieg et al., 2009 [3]
2	56/F	NA	ABC, 3TC, EFV	206	ND	RAEB	≥Int 2	Complex with del(5q) and monosomy 7	NA	Yes	NA	Takahashi et al., 2012 [4]
3	60/M	NA	ABC, 3TC, LPV	500	NA	RAEB (t‐MDS)	≥Int 2	Complex with del(5q) and monosomy 7	NA	Yes	NA	Takahashi et al., 2012 [4]
4	43/M	NA	NA	223	ND	RAEB	Int‐1	46,XY	NA	No	NA	Takahashi et al., 2012 [4]
5	55/M	23	RTV, DRV, TFC, TDF	500	ND	RA	Int‐2	Complex with monosomy 7	NA	Yes	NA	Takahashi et al., 2012 [4]
6	65/M	26	EFV, TFC, TDF	300	ND	RA	Int‐2	Complex with monosomy 5 and 7	NA	No	NA	Takahashi et al., 2012 [4]
7	50/M	NA	ABC, 3TC, TFC, TDF, LPV	231	NA	RA	Int‐2	46,XY,del (20)(q11)	NA	No	NA	Takahashi et al., 2012 [4]
8	51/M	NA	T20, FTC, TDF, RTV, CRV	254	>75,000	RAEB	Int‐2	47,XY,+ 21	NA	Yes	NA	Takahashi et al., 2012 [4]
9	56/F	NA	ATV, TFC, TDF	1,310	<40	RCMD	Int‐2	del(5q), del(7q), dic(9;12)	NA	Yes	Aza	Williamson et al., 2016 [5]
10	66/F	28	NA	573	52	MDS	Int‐1	46,XX	ASXL1, DNMT3A	No	Len, Elt	Kaner et al., 2019 [6]
11	45/M	4	NA	840	ND	t‐ MDS	Int‐2	NA	NA	Yes	Aza	Kaner et al., 2019 [6]
12	66/M	13	NA	383	73	MDS	Int‐2	del(7q)	ASXL1	No	Aza	Kaner et al., 2019 [6]
13	70/M	20	NA	76	247	t‐ MDS/ AML	Int‐2	−5, del(7q),−2	TP53	Yes	Aza	Kaner et al., 2019 [6]
14	49/M	11	NA	40	ND	MDS/ AML	Int‐2	NA	NA	Yes	Aza	Kaner et al., 2019 [6]
15	54/M	NA	NA	NA	NA	MDS	Int‐2	del(7q)	NA	Yes	Aza, Dec	Kaner et al., 2019 [6]
16	58/F	18	NA	484	ND	MDS	>Int 2	−7	NA	Yes	7+3/ HiDAC	Kaner et al., 2019 [6]
17	66/M	NA	NA	304	ND	t‐ MDS/ AML	Int‐2	del(20q)	ASXL1	No	Aza	Kaner et al., 2019 [6]
18	66/F	17	NA	781	ND	MDS	>Int 2	−7, −5, +8, +9	ASXL1, DNMT3A,	Yes	Aza	Kaner et al., 2019 [6]
19	52/F	12	NA	140	NA	t‐ MDS/ AML	Int‐2	NA	TP53	Yes	Aza	Kaner et al., 2019 [6]
20	56/M	NA	NA	390	ND	MDS	Int‐1	Normal	NA	No	Len, Elt	Kaner et al., 2019 [6]
21	64/F	15	NA	931	<40	MDS/ AML	Int‐2	del(7q)	ASXL1, TET2, DNMT3A, U2AF1	Yes	7+3	Kaner et al., 2019 [6]
22	55/M	24	NA	275	<40	t‐ MDS/ AML	>Int 2	Complex with ‐7	ASXL1, TP53, ETV6	Yes	7+3/ HiDAC, Dec	Kaner et al., 2019 [6]
23	65/F	2	NA	148	5,599	MDS	Int‐1	del(13q)	ND	No	Palliative	Kaner et al., 2019 [6]
24	61/F	16	AZT, 3TC, EFV	929	ND	MDS‐EB‐1	Int‐2	+8 with clonal karyotypic evolution hyperdiploidy with +8,+10,+21	ASXL1	No	Aza	This report

Abbreviations: 3TC, Lamivudine; ABC, Abacavir; AML, Acute myeloid leukemia; ART, Antiretroviral treatment; Aza, Azacitidine; AZT, Zidovudine; Dec, Decitabine, del, deletion; EFV, Efavirenz; Elt, Eltrombopag; F, Female; FTC, Emtricitabine; Int, Intermediate; IPSS, International Prognostic Scoring System; Len, Lenalidomide; LVR, Lopinavir; M, Male; MDS‐EB‐1, myelodysplastic syndrome with excess of blasts 1; NA, Not available; ND, Not detected; RA, Refractory anemia; RAEB, Refractory anemia with excess of blasts; RCMD, Refractory cytopenia with multilineage dysplasia; RTV, Ritonavir; T20, Enfuvirtide; t‐MDS, Therapy‐related myelodysplastic syndrome.

In this table, the patient collection included 2 case reports and 2 case series, beyond our case.